Болезнь Иценко-Кушинга: клиника, диагностика, дифференциальная диагностика, методы лечения

Клинические рекомендации по диагностике, дифференциальной диагностике и лечению болезни Ишенко-Кушинка, разработанные коллективом специалистов РФ.

болезнь Иценко, Кушинга, гиперкортицизм, опухоли гипофиза, диагностика, лечение

1. Марова Е.И., Арапова С.Д., Белая Ж.Е., и др. Болезнь Иценко-Кушинга: клиника, диагностика, лечение. - М.: 2012; стр 64.

2. Nieman LK, Biller BMK, Finding JW et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. // Clin Endocrinol Metab. 2008;93:1526-1540. doi: 10.1210/jc.2008-0125.

3. Biller BM, Grossman AB, Stewart PM et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. // Clin Endocrinol Metab. 2008;93:2454-2462. doi: 10.1210/jc.2007-2734.

4. Etxabe J, Vazguez JA. Morbidity and mortality in Cushing’s disease: an epidemiological approach. // Clin Endocrinol (Oxf). 1994;40:479-484. doi: 10.1111/j.1365-2265.1994.tb02486.x.

5. Plotz D, Knowlton AI, Ragan C. The natural history of Cushing’s disease. // Am J. Med. 1952;13:597-614. doi: 10.1016/0002-9343(52)90027-2.

6. O’Riordain DS, Farley DR, Young WF Jr et al. Long-term outcome of bilateral adrenalectomy in patients with Cushing’s syndrome. // Surgery. 1994;116:1088-1093.

7. Clyton RN. Mortality in Cushing’s disease. // Neuroendocrinology. 2010;92(1):71-76. doi: 10.1159/000315813.

8. Pivonello R, Melnichenko G, Zacharieva S et al. Mission study: an international observational study on the mortality in Cushing’s syndrome. // Endocrine Abstracts. 2011;26:32.

9. Белая Ж.Е. Ранняя диагностика эндогенного гиперкортицизма. Канонический wnt сигнальный путь и изменение костного метаболизма при глюкокортикоидном остеопорозе. Дисс. ... докт. мед. наук. - М.: 2013;293.

10. Белая Ж.Е., Рожинская Л.Я., Драгунова Н.В., и др. Метаболические осложнения эндогенного гиперкортицизма. Выбор пациентов для скрининга. // Ожирение и Метаболизм. 2013;(1):26-31. doi: 10.14341/2071-8713-5068

11. Valasi E, Santos A, Yaneva M et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. // European J Endocrinology. 2011;165:383-392. doi: 10.1530/EJE-11-0272.

12. Trifanescu R, Carsote M, Caragheorgheopol A et al. Screening for secondary endocrine hypertension in young patients. // Maedica (Buchar). 2013 Jun;8(2):108-115.

13. Omura M, Saito J, Yamaguchi K et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. // Hypertens Res. 2004;27:193-202. doi: 10.1291/hypres.27.193.

14. Catagri B, Rigaleau V, Poussin A et al. Occult Cushing’s syndrome in type-2 diabetes. // Clin Endocrinol Metab. 2003;88:5808-5813. doi: 10.1210/jc.2003-030254.

15. Leibowitz G, Tsur A, Chayen SD et al. Pre-clinical Cushing’s syndrome an unexpected frequent cause of poor glycaemic control in obese diabetic patients. // Clin Endocrinol (Oxf). 1996;44:717-722. doi: 10.1046/j.1365-2265.1996.737558.x.

16. Terzolo M, Reimondo G, Chiodini I et al. Screening of Cushing’s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. // Clin Endocrinol Metab. 2012 Oct;97(10):3467-3475. doi: 10.1210/jc.2012-1323.

17. Gungunes A, Sahin M, Demirci T et al. Cushing’s syndrome in type 2 diabetes patients with poor glycemic control. // Endocrine. 2014 Dec;47(3):895-900. doi: 10.1007/s12020-014-0260-8.

18. Антоненко М.И. Гиперкортицизм без специфических клинических симптомов: этиология, клиника, диагностика. Дисс. ... канд.мед.наук. - Ростов-на-Дону; 2014;141.

19. Волкова Н.И., Антоненко М.И., Ганенко Л.А. Первые данные по клинически скрытому синдрому Кушинга у больных сахарным диабетом 2 типа в России. // Врач-аспирант. 2013;59(4.2):299-305.

20. Chiodini I, Mascia ML, Muscarella S et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. // Ann Intern Med. 2007;147:541-548. doi: 10.7326/0003-4819-147-8-200710160-00006.

21. Moran C, Tapia MC, Hemandez E et al. Etiological review of hirsutism in 250 patients. Arch Med Res. 1994;25:311-314.

22. Diez-Perez A, Hooven FH, Adachi JD et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). // Bone. 2011;49:493-498. doi: 10.1016/j.bone.2011.05.007.

23. van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids in the United Kingdom. // QJM. 2000;93:105-111. doi: 0.1093/qjmed/93.2.105.

24. Дедов И.И. Клиническая нейроэндокринология. - М.: УП-Принт; 2011. 343 стр.

25. Дедов И.И., Мельниченко Г.А., Фадеев В.В. Эндокринология. Учебник. - М.; 2000.

26. Guechot J, Fiet J, Passa P et al.Physiological and pathological variations in saliva cortisol. // Hormone Research. 1982;16:357-364. doi: 10.1159/000179526.

27. Kahn JP, Rubinov DR, Davis CL et al. Salivary cortisol: a practical method for evaluation of adrenal function. // Biological Psychiatry. 1988;23:335-349. doi: 10.1016/0006-3223(88)90284-3.

28. Raff H, Raff JL, Finding JW. Late-night salivary cortisol as a screening test for Cushing’s syndrome. // Clin Endocrinol Metab. 1998;83:2681-2686. doi: 10.1210/jc.83.8.2681.

29. Raff H. Cushing’s syndrome: diagnosis and surveillance using salivary cortisol. // Pituitary. 2012;15:64-70. doi: 10.1007/s11102-011-0333-0.

30. Kivlighan KT, Granger DA, Schwartz EB, et al. Quantifying blood leakage into the oral mucosa and its effects on the measurement of cortisol, dehydroepiandrosterone, and testosterone in saliva. // Horm Behav. 2004;46:39-46. doi: 10.1016/j.yhbeh.2004.01.006.

31. Smith RE, Maquire JA, Stein-Oakley AN et al. Localization of 11β-hydroxisteroid dehydrogenase type II in human epithelial tissues. // Clin Endocrinol Metab. 1996;81:3244-3248.

32. Badrick E, Kirschbaum C, Kumari M. The relationship between smoking status and cortisol secretion. // Clin Endocrinol Metab. 2007;92:819-824. doi:10.1210/jc.2006-2155.

33. Erickson D, Natt N, Nippoldt T. et al. Dexamethasone-suppresed corticotrophin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. // Clin Endocrinol Metab. 2007;92:2972-2976. doi: 10.1210/jc.2006-2662.

34. Gatta B, Chabre O, Cortet C et al. Reevaluation of the combined dexamethasone suppression-corticotropin-releasing hormone test for differentiation of mild Cushing’s disease from pseudo-Cushing’s syndrome. // Clin Endocrinol Metab. 2007;92:4290-4293. doi:10.1210/jc.2006-2829.

35. Martin NM, Dhillo WS, Banerjee A et al. Comparison of the dexamethasone-suppressed corticotrophin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing’s syndrome. // Clin Endocrinol Metab. 2006;91:2582-2586. doi: 10.1210/jc.2005-2143.

36. Pecori Giraldi F, Pivonello R, Ambrogio AG et al. The dexamethasone-suppressed corticotrophin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. // Clin Endocrinol (Oxf). 2007;66:251-257. doi: 10.1111/j.1365-2265.2006.02717.x.

37. Magiakou MA, Mastorakos G, Oldfield EH et al. Cushing’s syndrome in children and adolescents. Presentation, diagnosis, and therapy. // N Engl J Med. 1994;331:629-636. doi: 10.1056/NEJM199409083311002.

38. Yanovski JA, Cutler GB, Jr. Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing’s syndrome from pseudo-Cushing’s states. // JAMA. 1993;269:2232-2238. doi: 10.1001/jama.1993.03500170062035.

39. Белая Ж.Е., Ильин А.В., Мельниченко Г.А., и др. Автоматизированный электрохемилюминисцентный метод определения кортизола в слюне для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. // Ожирение и метаболизм. 2011;27(2):56-63.

40. Wood PJ, Barth JH, Freedman DB et al. Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome - recommendations for a protocol for biochemistry laboratotories. // Ann Clin Biochem. 1997;34(Pt3):222-229. doi: 10.1177/000456329703400302.

41. Kidambi S, Raff H, Finding JW. Limitation of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing’s syndrome. // European J Endocrinology. 2007;157:725-731. doi: 10.1530/EJE-07-0424.

42. Putigano S, Toja P, Dubini A et al. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing’s syndrome. // Clin Endocrinol Metab. 2003;88:4153-4157. doi: 10.1210/jc.2003-030312.

43. Reimondo G, Allasino B, Bovio S et al. Evaluation of the effectiveness of midnight serum cortisol in the diagnostic procedures for Cushing’s syndrome. // Eur J Endocrinol. 2005;153:803-809. doi: 10.1530/eje.1.02042.

44. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А., и др. Возможности маркёра костного обмена - остеокальцина - для диагностики эндогенного гиперкортицизма и вторичного остеопороза. // Остеопороз и Остеопатии. 2011;(2):7-10.

45. Sereg M, Toke J, Patocs A et al. Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing’s syndrome. // Steroids. 2011;76:38-42. doi: 10.1016/j.steroids.2010.08.007.

46. Manenschijn L, Koper JW, van den Akker EL et al. A novel tool in the diagnosis and follow-up of (cyclic) Cushing’s syndrome: measurement of long-term cortisol in scalp hair. // Clin Endocrinol Metab. 2012;97:1836-1843. doi: 10.1210/jc.2012-1852.

47. Belaya ZE, Iljin AV, Melnichenko GA et al. Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. // Endocrine. 2012;41:494-500. doi: 10.1007/s12020-012-9658-3.

48. Белая Ж.Е., Ильин А.В., Мельниченко Г.А., и др. Определение уровня кортизола в слюне на автоматическом иммунохимическом анализаторе Cobas E601 (“Roche”) для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. // Клиническая лабораторная диагностика. 2011;(12):7-12.

49. Инструкция по определению кортизола in vitro в сыворотке, плазме крови, моче и слюне человека, каталожный номер 11875116122 для анализаторов Elecsys 1010, Elecsys 2010, Modular Analytics E170, Cobas e411, Cobas e601.

50. Jeyaraman K, Amini AC, Nandita G, Dwivedi SN. Late-night salivary cortisol in normal subjects and in patients with Cushing’s syndrome. // Postgraduate Medicine Journal. 2010;86:399-404. doi: 10.1136/pgmj.2009.090787.

51. Vogeser M, Durner J, Seliger E, Auernhammer C. Measurement of late-night salivary cortisol with an automated immunoassay system. // Clinical Chemistry and Laboratiry Medicine. 2006;44:1441-1445. doi: 10.1515/CCLM.2006.244.

52. Belaya ZE, Melnichenko GA. Practical evaluation of late-night salivary cortisol: a real-life approach. // Endocrine. 2012;42:222-223. doi: 10.1007/s12020-012-9709-9.

53. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А., и др. Современный взгляд на скрининг и диагностику эндогенного гиперкортицизма. // Проблемы эндокринологии. 2012;58(4):35-41. doi: 10.14341/probl201258435-41

54. Aniszewski JP, Young MF, Thompson GB et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. // World J Surgery. 2001;25:934-940. doi: 10.1007/s00268-001-0032-5.

55. Wajchenberg BL, Liberman B, Giannella Neto D et al. Growth hormone axis in Cushing’s syndrome. // Horm Res. 1996;45:99-107. doi: 10.1159/000184767.

56. Ilias I, Torpy DJ, Pacak K et al. Cushing’s syndrome due to ectopic corticotrophin secretion: twenty years’ experience at the National Institutes of Health. // Clin Endocrinol Metab. 2005;90:4955-4962. doi: 10.1210/jc.2004-2527.

57. Lad SP, Path CG, Laws ER, Katznelson L. The role of inferior petrosal sinus sampling in the diagnostic localization of Cushing’s disease. // Neurosurg Focus. 2007;23:1-6.

58. Utz A, Biller BMK. The role of bilateral inferior petrosal sinus sampling in the diagnosis of Cushing’s syndrome. // Arq Bras Endocrinol Metab. 2007;51:1329-1338. doi: 10.1590/S0004-27302007000800019.

59. Katznelson L, Bogan JS, Trob JR et al. Biochemical assessment of Cushing’s disease in patients with corticotroph macroadenomas. // Clin Endocrinol Metab. 1998;83:1619-1623. doi: 10.1210/jc.83.5.1619.

60. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. // Edocr Rev. 1998;19:647-672.

61. Finding JW, Raff H. Screening and diagnosis of Cushing’s syndrome. // Endocrinol Metabolism Clin North Am. 2005;38:385-402. doi: 10.1016/j.ecl.2005.02.001.

62. Hall WA, Luciano MG, Doppman JL et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. // Annual Internal Medicine. 1994;120:817-820. doi: 10.7326/0003-4819-120-10-199405150-00001.

63. Coulon G, Fellman D, Arbez-Gindre F, Pageaut G. Latent pituitary adenoma. Autopsy study. // Sem Hop. 1983;59:2747-2750.

64. Дедов И.И., Белая Ж.Е., Ситкин И.И., и др. Значение метода селективного забора крови из нижних каменистых синусов в дифференциальной диагностике АКТГ-зависимого гиперкортицизма. // Проблемы Эндокринологии. 2009;55(6):35-40. doi: 10.14341/probl200955635-40

65. Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613-619. doi: 10.1002/cncr.20412.

66. Ilias I, Chang R, Pacak K et al. Jugular venous sampling: An alternative to petrosal sinus sampling for the diagnostic evaluation of adrenocorticotropic hormone-dependent Cushing syndrome. // Clin Endocrinol Metab. 2004;89:3795-3800. doi: 10.1210/jc.2003-032014.

67. Isidori AM, Kaltsas GA, Pozza C et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. // Clin Endocrinol Metab. 2006;91:371-377. doi: 10.1210/jc.2005-1542.

68. Oldfield EH, Girton ME, Doppman JL. Absence of intercavernous venous mixing: evidence supporting lateralization of pituitary microadenomas by venous sampling. // Clin Endocrinol Metab. 1985;61:644-647. doi: 10.1210/jcem-61-4-644.

69. Oldfield EH, Chrousos GP, Schulte HM et al. Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. // New England J Medicine. 1985;312:100-103. doi: 10.1056/NEJM198501103120207.

70. Дедов И.И., Ситкин И.И., Белая Ж.Е. Первый опыт использования селективного забора крови из нижних каменистых синусов в России (клиническое наблюдение). // Проблемы эндокринологии. 2009;55)6):11-16. doi: 10.14341/probl200955611-16

71. Рожинская Л.Я., Белая Ж.Е., Ситкин И.И., и др. Возможности забора крови из нижних каменистых синусов в дифференциальной диагностике АКТГ-зависимого гиперкортицизма. / Сборник тезисов Всероссийский конгресс «Современные технологии в эндокринологии». 2009;126.

72. Белая Ж.Е., Рожинская Л.Я., Ситкин И.И., и др. Клинический случай АКТГ-эктопированного синдрома». // Вестник РОНЦ им. Н.Н.Блохина РАМН. 2010;21(4):46-51.

73. Ситкин И.И., Белая Ж.Е., Рожинская Л.Я., и др. Двухсторонний селективный забор крови из нижних каменистых синусов на фоне стимуляции десмопрессином в дифференциальной диагностике АКТГ-зависимого гиперкортицизма. // Диагностическая и интервенционная радиология. 2013;7(3):57-68.

74. Древаль А.В., Комердус И.В., Мурзина А.В., и др. Селективный забор крови из нижних каменистых синусов в дифференциальной диагностике АКТГ-зависимого гиперкортицизма (собственный клинический опыт). // Проблемы Эндокринологии. 2012;58(58):29-33. doi: 10.14341/probl201258229-33

75. Yanovski J, Cutler G J, Doppman J et al. The limited ability of inferior petrosal sinus sampling with corticotrophin releasing hormone to distinguish Cushing’s disease from pseudo-Cushing states or normal physiology. // Clin Endocrinol Metab. 1993;77:503-509.

76. Heaney AP, Melmed S. Molecular targets in pituitary tumors. // Nat Rev Cancer. 2004;4:285-295. doi: 10.1038/nrc1320.

77. Findling JW, Kehoe ME, Raff H. Identification of patients with Cushing’s disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: Prolactin as an index of pituitary venous effluent. // Clin Endocrinol Metab. 2004;89(12):6005-6009. doi: 10.1210/jc.2004-1378.

78. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А., и др. Роль градиента пролактина и АКТГ/пролактин нормализованного отношения для повышения чувствительности и специфичности селективного забора крови из нижних каменистых синусов для дифференциальной диагностики АКТГ-зависимого гиперкортицизма. // Проблемы Эндокринологии. 2013;59(4):3-10. doi: 10.14341/probl20135943-10.

79. Belaya Z, Sitkin I, Rozhinskaya L et al. Usefulness of Prolactin IPS/P ratio and dominant ACTH/Prolactin ratio in bilateral inferior petrosal sinus sampling with desmopressin stimulation in patients with ACTH-dependent Cushing’s syndrome. // Austrian J Clinical Endocrinology and Metabolism. 2012;5(3):21.

80. Белая Ж.Е., Драгунова Н.В., Рожинская Л.Я., и др. Низкотравматичные переломы у пациентов с эндогенным гиперкортицизмом. Предикторы и факторы риска, влияние на качество жизни. // Остеопороз и остеопатии. 2013;(1):7-13.

81. Belaya ZE, Rozhinskaya LY, Solodovnikov AG et al. Glucocorticoid-induced osteoporosis: fractures and bone remodeling in patients with endogenous Cushing’s syndrome. / Series: Endocrinology Research and Clinical Developments. Online Book, Published by Nova Science Publishers, Inc New-York. 2013, 55 pp; ISBN: 978-1-62948-341-2, online book

82. Lindsay JR, Jonklaas J, Oldfield EH, Nieman LK. Cushing’s syndrome during pregnancy: personal experience and review of the literature. // Clin Endocrinol Metab. 2005;90:3077-3083. doi: 10.1210/jc.2004-2361.

83. Гринева Е.Н. Заболевания гипофиза и беременность. // Бюллетень Федерального Центра сердца, крови и эндокринологии им. В.А. Алмазова. 2013;(2):23-28.

84. Molitich ME. // Pituitary tumors and pregnancy. GH IGF Res. 2003;13:38-44.

85. Pivonello R, De Martino MC, Auriemma RS et al. Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. // Endocrinol Invest. 2014;37:99-112. doi: 10.1007/s40618-013-0019-8.

86. Aron DC, Schnall AM, Sheeler LR. Cushing’s syndrome in pregnancy. // Obstet Gynecol. 1990;162:244-252. doi: 10.1016/0002-9378(90)90859-6.

87. Colao A, Boscaro M, Ferone D, Casanueva FF. Managing Cushing’s disease: the state of the art. // Endocrine. 2014 Sep;47(1):9-20. doi: 10.1007/s12020-013-0129-2.

88. Leach P, Abou-Zeid AH, Kearney T et al. Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. // Neurosurgery. 2010;67:1205-1212. doi: 10.1227/NEU.0b013e3181ef25c5.

89. Bertagna X, Guignat L. Approach to the Cushing’s disease patient with persistent/recurrent hypercortisolism after pituitary surgery. // Clinical Endocrinology Metabolism. 2013;98:1205-1212. doi: 10.1210/jc.2012-3200.

90. Boscaro M, Barzon F, Fallo F. Cushing’s syndrome. // Lancet. 2001;357(9258):783-791. doi: 10.1016/S0140-6736(00)04172-6.

91. Mampalam TJ, Tyrrell JB, Wilson CB. Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. // Ann Intern Med. 1988;109:487-493. doi: 10.7326/0003-4819-109-6-487.

92. Григорьев А.Ю., Азизян В.Н., Иващенко О.В., Надеждина Е.Ю. Повторная транссфеноидальная аденомэктомия при рецидиве и персистирующем течении болезни Иценко-Кушинга. // Нейрохирургия. 2014;2:49-53.

93. Friedman RB, Oldfield LK, Nieman. Repeat transsphenoidal surgery for Cushing’s disease. // Neurosurgery. 1989;71:520-527. doi: 10.3171/jns.1989.71.4.0520.

94. Benvensite RJ, King WA, Walsh J et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. // Neurosurg. 2005;102,:1004-1012. doi: 10.3171/jns.2005.102.6.1004.

95. Chee GH, Mathias DB, James RA, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? // Clin Endocrinol (Oxf). 2001;54:617-626. doi: 10.1046/j.1365-2265.2001.01261.x

96. Atkinson AB, Kennedy A, Wiggam MI et al. Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. // Clin Endocrinol (Oxf). 2005;63:549-559. doi: 10.1111/j.1365-2265.2005.02380.x.

97. Chen JC, Amar AP, Choi S et al. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. // Neurosurg. 2003;98:967-973. doi: 10.3171/jns.2003.98.5.0967.

98. Esposito F, Dusick JR, Cohan P et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. // Clin Endocrinol Metab. 2006;91:7-13. doi: 10.1210/jc.2005-1204.

99. Estrada J, Garcia-Uria J, Lamas C et al. The complete normalization of the adrenocortical function as the criterion of cure after transsphenoidal surgery for Cushing’s disease. // Clin Endocrinol Metab. 2001;86:5695-5699.

100. Hammer GD, Tyrrell JB, Lamborn KR et al. Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. // Clin Endocrinol Metab. 2004;89:6348-6357. doi: 10.1210/jc.2003-032180.

101. Pereira AM, van Aken MO, van Dulken H et al. Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing’s disease. // Clin Endocrinol Metab. 2003;88:5858-5864. doi: 10.1210/jc.2003-030751.

102. Rees DA, Hanna FW, Davies JS et al. Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. // Clin Endocrinol (Oxf). 2002;56:541-551. doi: 10.1046/j.1365-2265.2002.01511.x.

103. Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing’s disease: a single centre audit. // Clin Endocrinol (Oxf). 2002;56:25-31. doi: 10.1046/j.0300-0664.2001.01444.x.

104. Sonino N, Zielezny M, Fava GA et al. Risk factors and long-term outcome in pituitary-dependent Cushing’s disease. // Clin Endocrinol Metab. 1996;81:2647-2652.

105. Bruns C, Lewis I, Briner U et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. // Eur J Endocrinol. 2002 May;146(5):707-716. doi: 10.1530/eje.0.1460707.

106. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. // Endocr Rev. 2003;24:28-47. doi: 10.1210/er.2000-0001.

107. Colao A, Petersenn S, Newell-Price J et al. A 12-month phase 3 study of Pasireotide in Cushing’s disease. // NEJM. 2012;366: 914-924. doi: 10.1056/NEJMoa1105743.

108. Pivonello R, Arnaldi G, Scaroni C et al. Effectiveness of pasireotide treatment in patients with Cushing’s disease: a national experience based on clinical practice. / ENEA 2014;page 56, Abstract ID: 467, Sofia, Bulgaria.

109. MacKenzie Feder J, Bourdeau I, Vallette S et al. Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III trial. // Pituitary. 2014 Dec;17(6):519-29. doi: 10.1007/s11102-013-0539-4.

110. Henry RR, Mudaliar S, Hermosillo Reséndiz K et al. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. // Endocr Abstr. 2011;26:26.

111. Reznik AY, Bertherat J, Borson-Chazot F et al. Management of hyperglycaemia in Cushing’s disease: Experts’ proposals on the use of pasireotide. // Diabetes and Metabolism. 2013;39:34-41. doi: 10.1016/j.diabet.2012.10.005.

112. Colao A, Block CD, Caztambide MS et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. // Pituitary. 2014 Apr;17(2):180-6. doi: 10.1007/s11102-013-0483-3.

113. Godbout A, Manavela MP, Danilowicz K et al. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. // European J Endocrinology. 2010;163:709-716. doi: 10.1530/EJE-10-0382.

114. Lila AR, Gopal RA, Acharya SV. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. // Endocrine Practice. 2010;16:968-976. doi: 10.4158/EP10031.OR.

115. Pivonello R, De Martino MC, Cappabianca P et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. // Clinical Endocrinology and Metabolism. 2009;94:223-230. doi: 10.1210/jc.2008-1533.

116. Fleseriu M, Biller BMK, Findling JW et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s Syndrome. // JCEM. 2012;97:2039-2049. doi: 10.1210/jc.2011-3350.

117. Gadelha MR, Neto LV. Efficacy of medical treatment in Cushing’s disease: a systematic review. // Clinical Endocrinology. 2014;80:1-12. doi: 10.1111/cen.12345.

118. Mackley HB, Reddy CA, Lee SY et al. Intensity-modulated radiotherapy for pituitary adenomas. The preliminary report of the Cleveland Clinic experience. // Int J Radiat Oncol Biol Phys. 2007;67:232-239. doi: 10.1016/j.ijrobp.2006.08.039.

119. Kumar S, Burke K, Nalder C et al. Treatment accuracy of fractionated stereotactic radiotherapy. // Radiother Oncol. 2005;74:53-59. doi: 10.1016/j.radonc.2004.06.008.

120. Ding D, Starke R, Sheehan J. Treatment paradigms for pituitary adenomas: defining the roles of radiosurgery and radiation therapy. // Neurooncol. 2014;117:445-457. doi: 10.1007/s11060-013-1262-8.

121. Jagannathan J, Sheehan JP, Pouratian N et al. Gamma Knife surgery for Cushing’s disease. // Neurosurg. 2007;106(6):980-987. doi: 10.3171/jns.2007.106.6.980.

122. Марова Е.И., Манченко О.В., Воронцов А.В., и др. Опыт радиохирургического лечения пациентов с болезнью Иценко-Кушинга без выявленной аденомы гипофиза. // Проблемы эндокринологии. 2008;54(3):21-27.

123. Leenstra J, Shota T, Kline R. Factors associated with endocrine deficit after SRS of pituitary adenomas. // Neurosurgery. 2010;1:27-30. doi: 10.1227/01.NEU.0000370978.31405.A9.

124. Tsang RW, Brierley JD, Panzarella T et al. Radiation therapy for pituitary adenoma. Treatment outcome and prognostic factors. // Int J Radiat Oncol Biol Phys. 1994;30:557-565. doi: 10.1016/0360-3016(92)90941-A.

125. Becker G, Kocher M, Kortmann RD et al. Radiation therapy in the multimodal treatment approach of pituitary adenomas. // Strahlenther Onkol. 2002;178:173-186. doi: 10.1007/s00066-002-0826-x.

126. Laws ER, Sheehan JP, Sheehan JM et al. Stereotactic radiosurgery for pituitary adenomas. A review of the literature. // Neurooncol. 2004;69:257-272. doi: 10.1023/B:NEON.0000041887.51906.b7.

127. Rowe J, Grainger A, Walton L et al. Risk for malignancy after gamma knife stereotactic radiosurgery. // Neurosurgery. 2007;60:60-66. doi: 10.1227/01.NEU.0000255492.34063.32.

128. Morris LF, Harris RS, Milton DR et al. Impact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormone - dependent Cushing’s syndrome. // Surgery. 2013;154:1174-1184.

129. Ritzel K, Beuschlein F, Mickish A et al. Outcome of bilateral adrenalectomy in Cushing’s syndrome: a systematic review. // JCEM. 2013;98:3939- 3948. doi: 10.1210/jc.2013-1470.